World’s First Oral Cholesterol-Lowering Drug PCSK9 Inhibitor
The US Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), developed by Merck. It is the world’s first oral PCSK9 inhibitor, offering a daily pill alternative to injectable cholesterol-lowering drugs.
Key Highlights
- What it is: Lipfendra belongs to the class of PCSK9 inhibitors, which block a liver protein responsible for preventing the body from clearing “bad” (LDL) cholesterol from the blood.
- How it compares: Previously, PCSK9 inhibitors (like Repatha, Praluent, and Leqvio) were only available as biweekly or semi-annual injections. Lipfendra provides the same mechanism in a once-daily oral tablet.
- Effectiveness: In Phase 3 clinical trials, adding Lipfendra to standard statin therapy reduced LDL cholesterol levels by 56% to 59% over 24 weeks.
- Who it’s for: Adults with high LDL cholesterol—including those with heterozygous familial hypercholesterolemia (HeFH)—whose cholesterol remains elevated despite taking maximum tolerated statin doses.
How Lipfendra Fits into Cholesterol Treatment
| Medication Class | Administration | Mechanism of Action | Typical LDL Reduction |
| Statins (Standard 1st line) | Daily Pill | Reduces liver cholesterol production | 30% – 50% |
| Injectable PCSK9 Inhibitors | Injection (2–4 wks or 6 mos) | Blocks PCSK9 protein to help liver clear LDL | 50% – 60% |
| Lipfendra (Oral PCSK9) | Once-Daily Pill | Blocks PCSK9 protein (needle-free) | 56% – 59% |
Usage Note: Lipfendra is intended as an add-on therapy (typically alongside statins, ezetimibe, or diet changes) rather than a complete replacement for initial statin treatment. Additionally, it must be taken on an empty stomach.